 |
市場調查報告書
商品編碼
1528953
甲狀腺癌診斷市場規模- 按產品（儀器、套件和消耗品）、類型（乳頭狀癌、濾泡狀癌）、技術（血液檢測、影像、活體組織切片）、最終用途（醫院、癌症診斷中心）和預測，2024 年 - 2032Thyroid Cancer Diagnostics Market Size - By Product (Instruments, Kits and Consumables), Type (Papillary Carcinoma, Follicular Carcinoma), Technique (Blood Test, Imaging, Biopsy), End-use (Hospitals, Cancer Diagnostic Centers) & Forecast, 2024 - 2032 |
||||||
由於夥伴關係和合作的增加以及持續的技術進步，2024 年至 2032 年全球甲狀腺癌診斷市場規模將以 5.7% 的複合年成長率擴大。研究人員和醫療專業人員正在改進多種診斷方法，以提高準確性和早期檢測能力。他們正在整合先進的成像技術和分子生物標記來提高診斷準確性。
人工智慧驅動演算法的利用等快速進步也透過開發用於治療計劃和預後評估的下一代診斷工具來提高精確度。例如，2023 年 10 月，核醫領域的領導者 Curium 和 3D 超音波解決方案的先驅 PIUR IMAGING 合作，在德國推進甲狀腺癌診斷。
市場分為產品、類型、技術、最終用途和地區。
按產品類型分類，由於需要提高準確性和簡化診斷流程，預計從 2024 年到 2032 年，試劑盒和耗材領域的甲狀腺癌診斷市場將大幅成長。製造商正在開發創新的生物標記測定和成像劑，以提高檢測甲狀腺癌標記的靈敏度和特異性。此外，先進生物感測技術和小型化晶片實驗室設備的整合等發展正在擴大可用套件和耗材的範圍，以實現快速且經濟高效的測試。
癌症診斷中心最終用途領域的甲狀腺癌診斷產業預計將從 2024 年擴大到 2032 年。這些中心的醫療專業人員正在完善方案並採用新的方法來改善患者的治療結果。癌症診斷中心的不斷進步將進一步為患者提供更快、更準確的診斷和量身定做的治療策略，以確保更好地管理甲狀腺癌並提高整體存活率。
從地區來看，在監管支持和醫療基礎設施進步的推動下，歐洲甲狀腺癌診斷行業規模預計將在 2024 年至 2032 年間實現強勁成長。歐洲的監管框架正在不斷發展，以確保診斷技術的安全性和有效性，從而促進創新和採用。醫療保健基礎設施的改善也將促進該地區更多地獲得先進的診斷工具和專業知識。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 甲狀腺癌盛行率增加
- 癌症診斷技術的進步
- 透過篩檢計劃提高認知
- 產業陷阱與挑戰
- 嚴格的監管場景
- 甲狀腺癌診斷費用高
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按產品分類，2021 - 2032 年
- 主要趨勢
- 儀器儀表
- 套件和消耗品
第 6 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 乳頭狀癌
- 濾泡性癌
- 其他類型
第 7 章：市場估計與預測：按技術分類，2021 - 2032 年
- 主要趨勢
- 驗血
- 影像學
- 活體組織切片
- 其他技術
第 8 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 醫院
- 癌症診斷中心
- 學術及研究機構
- 其他最終用戶
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Abbott Laboratories
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Canon Inc.
- Danaher Corporation
- Esaote SPA
- F. Hoffmann-La Roche Ltd
- GE HealthCare
- Hologic, Inc.
- Illumina, Inc.
- Koninklijke Philips N.V.
- PerkinElmer, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Veracyte, Inc.
Global Thyroid Cancer Diagnostics Market size will expand at 5.7% CAGR from 2024 to 2032, due to increasing partnerships and collaborations alongside ongoing technological advancements. Researchers and medical professionals are improving several diagnostic methods to enhance accuracy and early detection capabilities. They are integrating advanced imaging techniques and molecular biomarkers to refine diagnostic accuracies.
Rapid advancements, such as the utilization of AI-driven algorithms are also enhancing precision through the development of next-generation diagnostic tools for treatment planning and prognostic assessment. For instance, in October 2023, Curium, a leader in nuclear medicine, and PIUR IMAGING, a pioneer in 3D ultrasound solutions, partnered to advance thyroid cancer diagnostics in Germany.
The market is segregated into product, type, technique, end-use, and region.
By product type, the thyroid cancer diagnostics market from the kits & consumables segment is estimated to rise at significant rate from 2024 to 2032 due to the need for improved accuracy and streamlined diagnostic processes. Manufacturers are developing innovative biomarker assays and imaging agents to enhance sensitivity and specificity in detecting thyroid cancer markers. In addition, developments like the integration of advanced biosensing technologies and miniaturized lab-on-a-chip devices are expanding the range of available kits and consumables for rapid and cost-effective testing.
Thyroid cancer diagnostics industry from the cancer diagnostic centers end-use segment is expected to expand from 2024 to 2032. This is owing to the increasing integration of state-of-the-art imaging technologies and molecular testing capabilities to enhance diagnostic accuracy and treatment planning. Medical professionals at these centers are refining protocols and adopting new methodologies to improve patient outcomes. The ongoing advancements in cancer diagnostic centers will further provide patients with faster, more accurate diagnoses and tailored therapeutic strategies for ensuring better management of thyroid cancer and improved overall survival rates.
Regionally, the Europe thyroid cancer diagnostics industry size is projected to depict robust growth between 2024 and 2032, propelled by regulatory support and advancements in healthcare infrastructure. Regulatory frameworks in Europe are evolving to ensure the safety and efficacy of diagnostic technologies for fostering innovation and adoption. Healthcare infrastructure improvements will also facilitate greater access to advanced diagnostic tools and expertise across the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of thyroid cancer
- 3.2.1.2 Advancement in cancer diagnostic technologies
- 3.2.1.3 Growing awareness through screening programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory scenario
- 3.2.2.2 High cost of thyroid cancer diagnosis
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.3 Kits and consumables
Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Papillary carcinoma
- 6.3 Follicular carcinoma
- 6.4 Other types
Chapter 7 Market Estimates and Forecast, By Technique, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Blood test
- 7.3 Imaging
- 7.4 Biopsy
- 7.5 Other techniques
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Cancer diagnostic centers
- 8.4 Academic and research institutes
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Agilent Technologies, Inc.
- 10.3 Bio-Rad Laboratories, Inc.
- 10.4 Canon Inc.
- 10.5 Danaher Corporation
- 10.6 Esaote SPA
- 10.7 F. Hoffmann-La Roche Ltd
- 10.8 GE HealthCare
- 10.9 Hologic, Inc.
- 10.10 Illumina, Inc.
- 10.11 Koninklijke Philips N.V.
- 10.12 PerkinElmer, Inc.
- 10.13 Siemens Healthineers AG
- 10.14 Thermo Fisher Scientific Inc.
- 10.15 Veracyte, Inc.
